RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Basilea Pharmaceutica AG Allschwil Stock

Basilea Pharmaceutica AG Allschwil Equity 2024

Basilea Pharmaceutica AG Allschwil Equity

-10 M CHF

Ticker

BSLN.SW

ISIN

CH0011432447

WKN

A0B9GA

In 2024, Basilea Pharmaceutica AG Allschwil's equity was -10 M CHF, a -51.71% increase from the -20.72 M CHF equity in the previous year.

Basilea Pharmaceutica AG Allschwil Aktienanalyse

What does Basilea Pharmaceutica AG Allschwil do?

Basilea Pharmaceutica AG is a leading biopharmaceutical company based in Basel, Switzerland. It was founded in 2000 and focuses on the research, development, and marketing of innovative drugs for the treatment of infectious diseases, cancer, and dermatological conditions. The company operates globally and currently employs over 200 employees. Basilea's main focus is on developing drugs that meet the specific needs of patients and medical professionals. It works closely with its partners and customers to ensure that its products meet the highest quality standards and meet the demands of patients. Basilea has two main divisions: infections and oncology. The company has a strong expertise in the development of antibiotics and antifungal drugs. One of its most well-known products is the antibiotic Ceftobiprol, which is used to treat bacterial infections such as pneumonia, skin, and bone infections. Another promising product is Isavuconazole, an antifungal drug used to treat fungal infections. In oncology, the business is divided into two important areas: the development and marketing of cancer drugs, and collaboration with other companies to develop tailored cancer therapies. The company works closely with other leading companies such as Pfizer, Roche, and GSK to expand its expertise in cancer research and development. Basilea's business model is based on the development of innovative drugs that meet the needs of patients and doctors. The company invests heavily in its research and development and aims to develop ethically sound and effective solutions for controlling infectious diseases and cancer. Through strategic partnerships and targeted marketing, it works to market its products worldwide and strengthen its position in the rapidly changing pharmaceutical market. Basilea sees itself as an innovative company that establishes itself in the market and plays a leading role in the industry. Its success is based on the concept of innovation, commitment, and growth. The company is committed to improving the quality of life for patients around the world by focusing on the development of new drugs that help fulfill important medical needs. Basilea Pharmaceutica AG remains committed to striving for excellence and innovation together with its partners and customers to advance the development of new treatment options. With this focus, Basilea will continue to play an important role in the industry and bring innovative drugs to the market that improve patients' lives and make the world a better place. Basilea Pharmaceutica AG Allschwil ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Basilea Pharmaceutica AG Allschwil's Equity

Basilea Pharmaceutica AG Allschwil's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Basilea Pharmaceutica AG Allschwil's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Basilea Pharmaceutica AG Allschwil's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Basilea Pharmaceutica AG Allschwil's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Basilea Pharmaceutica AG Allschwil’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Basilea Pharmaceutica AG Allschwil stock

What is the equity of Basilea Pharmaceutica AG Allschwil this year?

Basilea Pharmaceutica AG Allschwil has equity of -10 M CHF this year.

What was the equity of Basilea Pharmaceutica AG Allschwil compared to the previous year?

The equity of Basilea Pharmaceutica AG Allschwil has increased/decreased by -51.71% decreased compared to the previous year.

What impact does a high equity have on investors of Basilea Pharmaceutica AG Allschwil?

A high equity is advantageous for investors of Basilea Pharmaceutica AG Allschwil as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Basilea Pharmaceutica AG Allschwil?

A low equity can be a risk for investors of Basilea Pharmaceutica AG Allschwil, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Basilea Pharmaceutica AG Allschwil affect the company?

An increase in equity of Basilea Pharmaceutica AG Allschwil can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Basilea Pharmaceutica AG Allschwil affect the company?

A reduction in equity of Basilea Pharmaceutica AG Allschwil can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Basilea Pharmaceutica AG Allschwil?

Some factors that can affect the equity of Basilea Pharmaceutica AG Allschwil include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Basilea Pharmaceutica AG Allschwil so important for investors?

The equity of Basilea Pharmaceutica AG Allschwil is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Basilea Pharmaceutica AG Allschwil take to change the equity?

To change equity, Basilea Pharmaceutica AG Allschwil can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Basilea Pharmaceutica AG Allschwil pay?

Over the past 12 months, Basilea Pharmaceutica AG Allschwil paid a dividend of 5 CHF . This corresponds to a dividend yield of about 12.47 %. For the coming 12 months, Basilea Pharmaceutica AG Allschwil is expected to pay a dividend of 0 CHF.

What is the dividend yield of Basilea Pharmaceutica AG Allschwil?

The current dividend yield of Basilea Pharmaceutica AG Allschwil is 12.47 %.

When does Basilea Pharmaceutica AG Allschwil pay dividends?

Basilea Pharmaceutica AG Allschwil pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Basilea Pharmaceutica AG Allschwil?

Basilea Pharmaceutica AG Allschwil paid dividends every year for the past 0 years.

What is the dividend of Basilea Pharmaceutica AG Allschwil?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Basilea Pharmaceutica AG Allschwil located?

Basilea Pharmaceutica AG Allschwil is assigned to the 'Health' sector.

Wann musste ich die Aktien von Basilea Pharmaceutica AG Allschwil kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Basilea Pharmaceutica AG Allschwil from 6/21/2013 amounting to 5 CHF, you needed to have the stock in your portfolio before the ex-date on 4/11/2013.

When did Basilea Pharmaceutica AG Allschwil pay the last dividend?

The last dividend was paid out on 6/21/2013.

What was the dividend of Basilea Pharmaceutica AG Allschwil in the year 2023?

In the year 2023, Basilea Pharmaceutica AG Allschwil distributed 0 CHF as dividends.

In which currency does Basilea Pharmaceutica AG Allschwil pay out the dividend?

The dividends of Basilea Pharmaceutica AG Allschwil are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Basilea Pharmaceutica AG Allschwil

Our stock analysis for Basilea Pharmaceutica AG Allschwil Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Basilea Pharmaceutica AG Allschwil Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.